Cancer Center Support Grant-P30

描述（由申请人提供）：加州大学戴维斯分校癌症中心是一个与劳伦斯利弗莫尔国家实验室（LLNL）的综合项目，是加州大学戴维斯分校卫生系统（结合加州大学戴维斯医学院和加州大学戴维斯医学中心）和加州大学戴维斯分校支持下的矩阵组织。该癌症中心位于加州萨克拉门托的加州大学戴维斯医学中心校园内，该中心的行政、临床和研究设施由本次P30竞争性更新的首席研究员领导；2002年7月1日，最初的P30被授予癌症中心。癌症中心的186名成员来自加州大学戴维斯分校的教职员工，以及LLNL、美国农业部西部人类营养研究中心和加州公共卫生部的研究人员。加州大学戴维斯分校癌症中心成员的同行评审资金总额为81,918,736.00美元，其中21,771,164.00美元（直接费用）由NCI提供。其他提供会员资格的组织的研究人员也分别通过美国能源部、美国农业部和加利福尼亚州获得研究经费。在加州大学戴维斯分校癌症中心，研究分为六个项目：(1)分子肿瘤学，(2)比较肿瘤学，(3)癌症治疗学，(4)人口科学与健康差异，(5)前列腺癌，(6)生物医学技术。

DESCRIPTION (provided by applicant): The UC Davis Cancer Center, an integrated program with Lawrence Livermore National Labs (LLNL), is a matrix organization under the aegis of the UC Davis Health System (combining the UC Davis School of Medicine and the UC Davis Medical Center), and the University of California, Davis. Located on the campus of the UC Davis Medical Center in Sacramento, California, the cancer center's administrative, clinical and research facilities are under the leadership of the Principal Investigator of this P30 competitive renewal; an initial P30 was awarded to the Cancer Center on July 1, 2002. The Cancer Center draws its 186 members from the faculty of UC Davis and investigators at the LLNL, the USDA Western Human Nutrition Research Center and the California Department of Public Health. Peer-reviewed funding for UC Davis Cancer Center members totals $81,918,736.00 of which $21,771,164.00 (direct costs) is provided by the NCI. Investigators at the other organizations contributing membership are also provided research funding through the US Department of Energy, the US Department of Agriculture, and the State of California respectively. At the UC Davis Cancer Center, research is organized into six programs: (1) Molecular Oncology, (2) Comparative Oncology, (3) Cancer Therapeutics, (4) Population Sciences and Health Disparities, (5) Prostate Cancer, (6) Biomedical Technology. This competitive renewal for the P30 [Cancer Center Support Grant] proposes support for (1) senior leadership, (2) program leadership, (3) developmental programs, (4) administration, (5) planning and evaluation activities, (6) nine shared resources including genomics, optical biology, mouse biology, the clinical trials support unit, biostatistics, clinical and molecular pharmacology, animal imaging, biospecimen repository and combinatorial chemistry, (7) the Protocol Review and Monitoring System, (8) protocol-specific research, and (9) Data Safety and Monitoring.